Friday, March 29, 2024
HomeearningsBayer drugs secure earnings beat, offset weak crop chems

Bayer drugs secure earnings beat, offset weak crop chems

Bayer, the German drugmaker trying to acquire U.S. seed company Monsanto, surpassed second-quarter earnings expectations and raised its guidance for the year as strong gains in stroke prevention pill Xarelto offset sluggish farming pesticides markets.

Second-quarter profit before interest, taxes, depreciation and amortization (EBITDA), adjusted for one-off items, gained 5.7 percent to 3.05 billion euros ($3.35 billion), above the average estimate of 2.90 billion in a Reuters poll among analysts.

Schöning | ullstein bild | Getty Images

Bayer, the inventor of aspirin and maker of Yasmin birth control pills, said it now expected EBITDA before special items to increase by a high-single-digit percentage, where it had previously seen a mid-single-digit gain.

Xarelto, which competes in blood clot prevention with Bristol Myers-Squibb and Pfizer's Eliquis, saw sales jumped 30 percent excluding currency swings to 703 million euros, well above expectations.

RELATED ARTICLES
- Advertisment -

Most Popular